Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | FPR1 | P21462 | 7/20 | 0.38 |
| ▸ | FPR2 | P25090 | 5/20 | 0.38 |
| ▸ | CPS1 | P31327 | 6/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1919904 | 0.91 | MC4R (0.45) | MC4RKDM4ESTAT3FPR1FPR2 | |
| SCHEMBL1919957 | 0.90 | MC4R (0.49) | MC4R | |
| SCHEMBL12536917 | 0.83 | FPR1 (0.40) | MC4RFPR1FPR2CPS1DPP4 | |
| SCHEMBL15039514 | 0.82 | KDM4E (0.39) | MC4RKDM4ESTAT3FPR1FPR2 | |
| SCHEMBL12536913 | 0.82 | KMT2A (0.47) | MC4RFPR1FPR2DPP4 | |
| SCHEMBL12536903 | 0.80 | PANK3 (0.44) | MC4RDPP4 | |
| SCHEMBL1948146 | 0.80 | MC4R (0.52) | MC4RDPP4 | |
| SCHEMBL13493164 | 0.79 | MC4R (0.52) | MC4R | |
| SCHEMBL3262709 | 0.79 | MC4R (0.52) | MC4R | |
| SCHEMBL1945992 | 0.77 | KDM4E (0.43) | MC4RKDM4ESTAT3FPR1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | ANDREWS MARK DAVID | 2011-06-09 | — | — | US | disclosed |
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | ANDREWS MARK DAVID | 2011-06-09 | — | — | US | disclosed |
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | ANDREWS MARK DAVID | 2011-06-09 | — | — | US | disclosed |
| WO-2010015972-A1 | DIAZEPINE AND DIAZOCANE COMPOUNDS AS MC4 AGONISTS | PFIZER LIMITED (GB) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | MC4R, CHRM4, GPR4 | MC4R 1/4885KDM4E 804/4885STAT3 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.